A fusidic acid phospholipid complex and its preparation method and use
By preparing the complex of fusidic acid and phospholipid, the problem of fusidic acid being poor in antibacterial effect on Gram-negative bacteria was solved, significantly improved its solubility and antibacterial properties, and broadened its application scope, especially for the large intestine Bacillus and Pseudomonas aeruginosa have a significant inhibitory effect.
Patent Information
- Application Number
- CN202311220439.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-09-20
AI Technical Summary
In the prior art, fusidic acid has little antibacterial effect on gram-negative bacteria, mainly because it cannot penetrate the outer membrane protective barrier of bacteria. No relevant preparation of fusidic acid phospholipid complex to enhance its antibacterial properties. Report.
A phospholipid complex of fusidic acid and different molar ratios was prepared, and the solvent was dissolved in an organic solvent and removed under reduced pressure to form a phospholipid complex of fusidic acid, which was used to inhibit Gram-negative bacteria. The specific method includes stirring fusidic acid and phospholipid at 20-60°C, and removing the organic solvent by reduced pressure to obtain a complex with a molar ratio of 1:0.1 to 1:5 for the fight against E. coli and aeruginosa. Cell bacteria and other bacteria.
It significantly improves the solubility of fusidic acid and its antibacterial effect on Gram-negative bacteria, enhances its antibacterial properties, and can achieve an antibacterial rate of up to 99.97% at specific concentrations, resulting in significant results on Gram-negative bacteria. Inhibitory effect.
Smart Images

Figure CN117017999B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a fusidic acid phospholipid complex and a preparation method and application thereof. Background Art
[0002] Since Fleming discovered penicillin in 1929, the invention of various antibiotics has had a huge impact on human health. However, with the widespread use of antibiotics, the emergence of bacterial resistance has posed a serious threat to humans. In 2017, the WHO published a list of drug-resistant pathogens, most of which are Gram-negative bacteria.
[0003] Fusidic acid, also known as brown mold acid, is a lipid-soluble steroid-like substance isolated and discovered by Godtfredsen et al. from the culture fluid of Fusidiella crimsonii in 1962. It is similar in structure to cephalosporin P1 and fumagillic acid. It exhibits antibacterial properties by binding to elongation factor G, preventing its release from ribosomes and inhibiting bacterial protein synthesis, but it mainly acts on Gram-positive bacteria. Therefore, since the 1960s, it has been widely used in the treatment of Gram-positive bacterial infections such as skin and bone joints. However, fusidic acid has almost no effect on Gram-negative bacteria, mainly because the outer membrane of Gram-negative bacteria has a protective and barrier effect. At the same time, there is no report on the preparation of fusidic acid phospholipid complexes to enhance the antibacterial activity of fusidic acid against Gram-negative bacteria. Summary of the invention
[0004] In view of the above-mentioned deficiencies in the prior art, the present invention provides a fusidic acid phospholipid complex and a preparation method and use thereof. The fusidic acid phospholipid complex prepared in the present application can effectively inhibit Gram-negative bacteria and enhance the antibacterial activity of fusidic acid against Gram-negative bacteria.
[0005] To achieve the above purpose, the technical solution adopted by the present invention to solve the technical problem is:
[0006] A fusidic acid phospholipid complex comprises fusidic acid and phospholipid.
[0007] Furthermore, the molar ratio of fusidic acid to phospholipid is 1:0.1 to 1:5.
[0008] Furthermore, the molar ratio of fusidic acid to phospholipid is 1:0.5 to 1:3.
[0009] Furthermore, the molar ratio of fusidic acid to phospholipid is 1:1.
[0010] Furthermore, the molar ratio of fusidic acid to phospholipid is 1:0.5.
[0011] Furthermore, the phospholipids are natural phospholipid components or phospholipids obtained by synthetic means.
[0012] Furthermore, the phospholipid is soybean lecithin, egg yolk lecithin, DSPE, DPPE, DSPC, DPPC, DSPG, DPPA, DOTAP, DEPC, DPPG or DSPE-MPEG2000.
[0013] The preparation method of the above-mentioned fusidic acid phospholipid complex is as follows:
[0014] Fusidic acid and phospholipid are dissolved in an organic solvent, then stirred at 20-60°C, and then the organic solvent is removed under reduced pressure to obtain a fusidic acid phospholipid complex.
[0015] Furthermore, the organic solvent is at least one of ethyl acetate, acetone, chloroform, dichloromethane, tetrahydrofuran, n-hexane, ethanol and methanol.
[0016] Further, the temperature is 55°C.
[0017] The use of the fusidic acid phospholipid complex in preparing an antibacterial agent capable of inhibiting Gram-negative bacteria.
[0018] Further, the Gram-negative bacteria is Escherichia coli 、 Pseudomonas aeruginosa or Proteus.
[0019] Beneficial effects of the present invention:
[0020] As the main component of biological membranes, phospholipids play an important role in the life activities of organisms. Structurally, phospholipid molecules are composed of a polar head and a hydrophobic tail. Since the free hydroxyl oxygen atoms on the phosphorus atoms have a strong tendency to gain electrons and the nitrogen atoms on the polar head have a strong tendency to lose electrons, they can form a complex with substances with specific structures in a certain proportion in a non-proton system - a phospholipid complex, which significantly improves the physical properties of the drug without changing its structure. Under certain conditions, it can be released to play a role.
[0021] The present invention prepares a fusidic acid phospholipid complex, which is a complex formed by fusidic acid and phospholipid under certain conditions and is a molecular complex. Since the chemical structure of the drug itself in the complex is not changed, the drug still has the original pharmacological activity. When the complex acts on Gram-negative bacteria, the phospholipid in the complex can protect fusidic acid from being bound by the outer membrane of the bacterial cell, thereby helping fusidic acid to enter the cytoplasm and exert an antibacterial effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 is the solubility of fusidic acid (FA) and fusidic acid phospholipid complex (FA-PC, 1:0.5 and 1:1) in water;
[0023] Figure 2 The antibacterial effects of fusidic acid (FA), fusidic acid phospholipid complex (FA-PC, 1:1), and phospholipid (PC) on Gram-negative bacteria Escherichia coli;
[0024] Figure 3 The antibacterial effects of fusidic acid (FA), fusidic acid phospholipid complex (FA-PC, 1:1), and phospholipid (PC) against Gram-negative bacteria Pseudomonas aeruginosa. DETAILED DESCRIPTION
[0025] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.
[0026] Example 1
[0027] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0028] Take 13.4 mg of fusidic acid and 20.3 mg of soybean lecithin, dissolve them together in 5 mL of anhydrous ethanol, stir them magnetically at 55°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol at 55°C under reduced pressure for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to soybean lecithin of 1:1.
[0029] Example 2
[0030] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0031] Take 13.4 mg of fusidic acid and 10.2 mg of soybean lecithin, dissolve them together in 5 mL of anhydrous ethanol, stir magnetically at 50°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol under reduced pressure at 50°C for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to soybean lecithin of 1:0.5.
[0032] Example 3
[0033] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0034] Take 13.4 mg of fusidic acid and 20.3 mg of egg yolk lecithin, dissolve them together in 5 mL of anhydrous ethanol, stir magnetically at 60°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol at 50°C under reduced pressure for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to egg yolk lecithin of 1:1.
[0035] Example 4
[0036] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0037] Take 13.4 mg of fusidic acid and 20.3 mg of DSPC, dissolve them together in 5 mL of anhydrous ethanol, stir them magnetically at 60°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol under reduced pressure at 50°C for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to DSPC of 1:1.
[0038] Example 5
[0039] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0040] Take 13.4 mg of fusidic acid and 20.3 mg of DSPG, dissolve them together in 5 mL of anhydrous ethanol, stir them magnetically at 60°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol under reduced pressure at 50°C for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to DSPG of 1:1.
[0041] Example 6
[0042] A fusidic acid phospholipid complex, the preparation method of which is as follows:
[0043] Take 13.4 mg of fusidic acid and 20.3 mg of DPPG, dissolve them together in 5 mL of anhydrous ethanol, stir them magnetically at 60°C for 2 hours to obtain a transparent clear liquid, and then remove the anhydrous ethanol under reduced pressure at 50°C for 30 minutes to obtain a fusidic acid phospholipid complex with a molar ratio of fusidic acid to DPPG of 1:1.
[0044] Experimental example
[0045] 1. The solubility of the fusidic acid phospholipid complexes prepared in Example 1 and Example 2 was tested. The results are shown in Figure 1 .
[0046] Depend on Figure 1 It can be seen that the formation of a complex with phospholipids can significantly increase the solubility of fusidic acid in water, and the solubility increases with the increase of phospholipid content.
[0047] 2. Take the E. coli strain, centrifuge it at 20℃ and 1800rcf for 15min, discard the supernatant, resuspend the precipitate with 1ml LB medium solution, and dilute it to a bacterial concentration of 5×10 5cfu / ml. Take 200 μL of bacterial solution, add fusidic acid (FA) aqueous solution, fusidic acid phospholipid complex (FA-PC, 1:1) aqueous solution, phospholipid (PC) aqueous solution, culture at 37°C for 12 hours, then take 100 μL of sample and dilute to appropriate concentration, evenly spread on LB agar solid culture medium plate, culture at 37°C for 24 hours, then count the number of colonies formed on the plate (CFU), and then quantitatively analyze the antibacterial effect, see Figure 2 .
[0048] Depend on Figure 2 It can be seen that fusidic acid (FA) and phospholipids (PC) have no antibacterial activity at all concentrations, while the fusidic acid phospholipid complex (FA-PC) prepared by the method of the present invention begins to have weak antibacterial activity at 5 μg / ml (inhibition rate 55%), the inhibition rate reaches 97% at 10 μg / ml, and reaches 99.97% at 20 μg / ml.
[0049] 3. Take the Pseudomonas aeruginosa strain, centrifuge it at 20℃ and 1800rcf for 15min, discard the supernatant, resuspend the precipitate in 1ml LB medium solution, and dilute it to a bacterial concentration of 5×10 5 cfu / ml. Take 200 μL of bacterial solution, add fusidic acid (FA) aqueous solution, fusidic acid phospholipid complex (FA-PC, 1:1) aqueous solution, phospholipid (PC) aqueous solution, culture at 37°C for 12 hours, then take 100 μL of sample and dilute to appropriate concentration, evenly spread on LB agar solid culture medium plate, culture at 37°C for 24 hours, then count the number of colonies formed on the plate (CFU), and then quantitatively analyze the antibacterial effect, see Figure 3 .
[0050] Depend on Figure 3 It can be seen that fusidic acid (FA) and phospholipids (PC) have no antibacterial activity at all concentrations, while the fusidic acid phospholipid complex (FA-PC) prepared by the method of the present invention begins to have weak antibacterial activity at 10 μg / ml (inhibition rate>60%), and has significant antibacterial activity at 20 μg / ml (inhibition rate>90%).
[0051] In summary, the preparation method of the fusidic acid phospholipid complex described in the present invention is simple, can significantly improve the solubility of fusidic acid and the antibacterial effect on Gram-negative bacteria, and can effectively broaden the antibacterial spectrum and application range of fusidic acid.
Claims
1. A fusidic acid phospholipid complex, characterized in that: The invention comprises fusidic acid and phospholipids in a molar ratio of 1:0.1 to 1:5; the phospholipids are soybean lecithin, egg yolk lecithin, DSPE, DPPE, DSPC, DPPC, DSPG, DPPA, DOTAP, DEPC, DPPG or DSPE-MPEG2000; The preparation method of the fusidic acid phospholipid complex is as follows: The fusidic acid and phospholipid are dissolved in an organic solvent, then stirred at 20-60°C, and then the organic solvent is removed under reduced pressure to prepare the fusidic acid phospholipid complex.
2. The fusidic acid phospholipid complex according to claim 1, characterized in that The molar ratio of fusidic acid to phospholipid is 1:0.5-1:
3.
3. The fusidic acid phospholipid complex according to claim 2, characterized in that: The molar ratio of fusidic acid to phospholipid is 1:
1.
4. The fusidic acid phospholipid complex according to claim 1, characterized in that: The organic solvent is at least one of ethyl acetate, acetone, chloroform, dichloromethane, tetrahydrofuran, n-hexane, ethanol and methanol.
5. Use of the fusidic acid phospholipid complex according to any one of claims 1 to 4 in the preparation of an antibacterial agent for inhibiting Gram-negative bacteria, characterized in that: The Gram-negative bacteria are Escherichia coli or Pseudomonas aeruginosa.
